|
1. Biologie
|
|
|
Science Snaps: spotting lung cancers’ ‘crime hotspots’ [Cancer Research UK]
|
|
|
|
|
|
Their
aim is to understand how the body’s immune system responds to cancer as
it evolves and develops. “Cancer cells don’t live alone, and we need to
understand how they interact and the evolutionary pressure they’re
under, to be able to stay one step ahead and anticipate cancer’s next
move,” she says.
|
|
|
|
|
|
|
1.4 Biologie - Technos
|
|
|
An outsider claimed to make genome-editing history — and the world snapped to attention [STAT]
|
|
|
|
|
|
In
2010, a Rice University graduate student named He Jiankui published a
paper describing the nitty-gritty details of a then-arcane bacterial
immune system called CRISPR. It was well before scientists unlocked the
knowledge that CRISPR could be used to manipulate DNA with a precision
and ease that other genome editors lacked. Now, just eight years later,
and after returning to his native China, He has burst onto the global
stage in the most spectacular way.
|
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues [Xconomy]
|
|
|
|
|
|
Basket
trials are a fairly new phenomenon in oncology and have their share of
skeptics. This essay in the New England Journal of Medicine in 2015, for
instance, warned that the small number of patients in each arm of a
basket study could lead to “over-interpretation” of the results from any
one arm. Loxo’s results are an example of relying on those types of
data.
|
|
|
|
|
|
|
|
|
|
|
|
5.8 ASH
|
|
|
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More [Xconomy]
|
|
|
|
|
|
Using
the previews of major studies that were released earlier this month,
we’ll dive into five of the disease areas under scrutiny at ASH this
year—leukemia/lymphoma, multiple myeloma, beta-thalassemia, hemophilia,
and sickle cell disease—and give you plenty of background in case you
haven’t been following each one closely.
|
|
|
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
5.8.4 ASH - CAR T
|
|
|
|
6.1 Observation
|
|
|
|
Cancer care: England still lagging behind the best [BBC News]
|
|
|
|
|
|
The
review by the Health Foundation of the government's record between 1995
and 2015 said that despite four strategies setting ambitious goals, the
NHS was still lagging behind the best. It said if services were
improved, 10,000 lives could be saved each year.
|
|
|
|
|
|
|
6.2 Implants mammaires
|
|
|
|
|
|
6.6 Publications
|
|
|
European funders detail their open-access plan [Science]
|
|
|
|
|
|
The
guidance aims to explain practicalities and “sets things straight,”
said Robert-Jan Smits, the European Commission’s OA envoy and one of the
creators of Plan S, at a news briefing in London today. Referring to
the often-acrimonious debate that has emerged since Plan S was released
on 4 September, he admitted to a “lack of clear communication” from his
side.
|
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|
|
6.9 Controverses
|
|
|
|
|
RCS statement on medical device regulation [Royal College of Surgeons]
|
|
|
|
|
|
The
RCS believes that all new surgical procedures and devices should be
registered, with related data collected in the appropriate national
audits, before they are routinely offered to patients. All implantable
devices should be registered and tracked to monitor efficacy and patient
safety in the long-term. This requires Government funding and support,
and potentially national guidelines on the introduction of new
procedures and technologies.
|
|
|
|
|
|